Skip to content

Assessing the clinical- and cost-effectiveness of facet-joint injections in selected patients with non-specific low back pain

A multicentre double-blind randomised controlled trial to assess the clinical- and cost-effectiveness of facet-joint injections in selected patients with non-specific low back pain: a feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN12191542
Enrollment
150
Registered
2014-01-03
Start date
2014-04-01
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain Musculoskeletal Diseases Low back pain

Interventions

Patients will be recruited from pain clinics at the three participating NHS centres and their associated community-based pain clinics. Patients will be referred by their general practitioners with low

Sponsors

NIHR Health Technology Assessment Programme - HTA (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 70 years attending pain clinics identified during routine clinical assessment of nonspecific low back pain 2. Low back pain of greater than three months? duration 3. Average pain intensity score of 4/10 or more in the seven days preceding recruitment despite NICE-recommended treatment 4. Dominantly paraspinal (not midline) tenderness at two bilateral lumbar levels 5. At least two components of NICE-recommended best non-invasive care completed, including education and one of a physical exercise programme, acupuncture and manual therapy

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. More than four painful lumbar facet-joints 3. Patient has not completed at least two components of NICE-recommended best non-invasive care 4. 'Red flag' signs 5. Hypersensitivity to study medications or X-ray contrast medium 6. Radicular pain 7. Dominantly midline tenderness over the lumbar spine 8. Any other dominant pain 9. Any major systemic disease or mental health illness that may affect the patient?s pain, disability and/or their ability to exercise and rehabilitate 10. Any active neoplastic disease, including primary or secondary neoplasm 11. Pregnant or breastfeeding patients 12. Previous lumbar facet-joint injections 13. Previous lumbar spinal surgery 14. Patients with morbid obesity (body mass index of 35 or greater) 15. Major trauma or infection to the lumbar spine 16. Participation in another clinical trial in the past 30 days 17. Patients unable to commit to the six-month study duration 18. Patients involved in legal actions or employment tribunals related to their low back pain 19. Patients with a history of substance abuse

Design outcomes

Primary

MeasureTime frame
To assess the eligibility criteria, recruitment and retention of patients in the two treatment arms (FJI versus sham procedure)

Secondary

MeasureTime frame
1. To assess the feasibility and acceptability of the two treatment arms from the point of view of patients and their pain teams 2. To assess the feasibility of the proposed definitive trial design including: 2.1. Testing of randomisation and blinding procedures 2.2. Development of an appropriate active and sham procedure for FJIs 2.3. Assessment of the consistency of the trial sites to deliver the combined physical and psychological programme 2.4. Ability to collect the outcomes proposed for the main trial (pain, functioning, health-related quality of life, anxiety and depression, healthcare resource utilisation, complications and adverse events) 3. To estimate outcome standard deviation to inform the power calculation for a definitive trial 4. To finalise the protocol design, statistical plan, number of centres required and study duration of the definitive trial

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026